Hospital
UCSF Health Community Hospitals
UCSF Health Community Hospitals was paid $7.40M by Medicaid between Jan 2018 and Dec 2024, across 95 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoUCSF HEALTH COMMUNITY HOSPITALS
SAN FRANCISCO, CA 94117
SAN FRANCISCO, CA 94117
33aNPI1174667158assigned 02/16/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.40M
24GClaims127,787
24DCodes billed95
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#204 of 410
Median peer was paid$6.90M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,339 | $869K | |
| 2019 | 23,645 | $831K | |
| 2020 | 13,963 | $680K | |
| 2021 | 17,055 | $863K | |
| 2022 | 14,367 | $978K | |
| 2023 | 19,737 | $1.84M | |
| 2024incomplete | 13,681 | $1.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 3,779 | 3,434 | $933K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 9.1% | 9,926 | 7,994 | $670K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.0% | 3,600 | 3,211 | $667K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.9% | 868 | 817 | $661K |
| A9150 | Non-prescription drugs | 7.4% | 3,265 | 1,272 | $545K |
| 80053 | Comprehensive metabolic panel | 5.4% | 7,438 | 6,831 | $400K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 4.9% | 8,002 | 4,890 | $360K |
| 0510 | 4.4% | 5,175 | 3,753 | $324K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 2,746 | 2,485 | $309K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 1,465 | 1,408 | $248K |
| 0450 | Emergency room services | 2.4% | 1,935 | 1,722 | $181K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 955 | 932 | $179K |
83 more codes
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.0% | 990 | $152K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 5,073 | $123K |
| 99199 | Unlisted special service, procedure or report | 1.6% | 1,817 | $116K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 2,584 | $113K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 1,773 | $108K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 261 | $107K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 8,035 | $96K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 1,728 | $91K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,903 | $79K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 948 | $78K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 407 | $72K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,805 | $63K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 482 | $60K |
| J3490 | Unclassified drugs | <1% | 2,542 | $57K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,076 | $53K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,978 | $49K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,818 | $43K |
| 84484 | <1% | 3,017 | $39K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 378 | $37K |
| 0760 | <1% | 506 | $34K | |
| 97139 | <1% | 1,439 | $31K | |
| 82962 | <1% | 2,729 | $28K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,477 | $20K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,078 | $17K |
| 83880 | <1% | 469 | $16K | |
| 94760 | <1% | 3,911 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 748 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,425 | $14K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 81 | $14K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 264 | $13K |
| 81001 | <1% | 1,715 | $13K | |
| 80061 | Lipid panel | <1% | 1,020 | $12K |
| 83690 | <1% | 1,838 | $11K | |
| 80047 | <1% | 114 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 128 | $10K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 635 | $8K |
| 0270 | <1% | 604 | $7K | |
| 90686 | <1% | 465 | $7K | |
| A9270 | Non-covered item or service | <1% | 1,862 | $7K |
| 90674 | <1% | 307 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,082 | $6K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 88 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 811 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 391 | $5K |
| 83605 | <1% | 474 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 55 | $4K |
| 85610 | <1% | 877 | $3K | |
| 81003 | <1% | 230 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 755 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 41 | $3K |
| 97750 | <1% | 67 | $3K | |
| 83735 | <1% | 471 | $3K | |
| 81002 | <1% | 161 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14 | $2K |
| Z7502 | <1% | 54 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 321 | $2K |
| 72131 | <1% | 14 | $2K | |
| 81025 | <1% | 136 | $2K | |
| 0002A | <1% | 47 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 17 | $1K |
| 90715 | <1% | 39 | $1K | |
| 87631 | <1% | 12 | $888.05 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 31 | $887.53 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 39 | $818.05 |
| 0001A | <1% | 43 | $686.07 | |
| 87040 | <1% | 71 | $625.89 | |
| 0003A | <1% | 15 | $600.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 27 | $552.27 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 62 | $523.01 |
| 71020 | <1% | 29 | $485.19 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 73 | $400.26 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 33 | $337.61 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 13 | $309.26 |
| 82043 | <1% | 26 | $184.42 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 31 | $178.42 |
| 87186 | <1% | 41 | $156.31 | |
| 85027 | <1% | 42 | $143.28 | |
| 85730 | <1% | 51 | $139.95 | |
| 71010 | <1% | 14 | $93.42 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12 | $92.16 |
| 91300 | <1% | 13 | $0.08 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 14 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 366 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORENO, FERNANDO (CFO/DIRECTOR)
Parent organizationUCSF HEALTH COMMUNITY HOSPITALS
| Provider | Location | Paid |
|---|---|---|
| UCSF Health Community Hospitals | San Francisco, CA | $14.95M |
| UCSF Health Community Hospitals | San Francisco, CA | $256K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.